Search Within

Han Xiao

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
Groups
  1. Biostatistics Service (16)
  2. Department of Medicine (16)
  3. Epidemiology and Biostatistics (16)
  4. Genitourinary Oncology Service (16)
  5. Solid Tumor Oncology Division (16)
  6. Population Sciences Research Program (6)

More Groups

People
  1. Glenn Heller (7)
  2. Michael Morris (7)
  3. Arlyn Apollo (4)
  4. Jun Mao (4)
  5. Katherine Panageas (4)
  6. Kevin Liou (4)

More People

Years
  1. 2024 (3)
  2. 2023 (5)
  3. 2022 (2)
  4. 2020 (2)
  5. 2019 (1)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (10)
  2. Annals of Oncology (2)
  3. BMJ Open (1)
  4. Cancer (1)
  5. JAMA Network Open (1)
  6. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (10)
  2. Oxford University Press (3)
  3. American Medical Association (1)
  4. BMJ Publishing Group Ltd. (1)
  5. Wiley Blackwell (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Journal Article

    Feldman, D. R.; Ged, Y.; Lee, C. H.; Knezevic, A.; Molina, A. M.; Chen, Y. B.; Chaim, J.; Coskey, D. T.; Murray, S.; Tickoo, S. K.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors: The PEACE randomized controlled trial
    Meeting Abstract

    Mao, J. J.; Liou, K.; Panageas, K.; Baser, R. E.; Romero, S. A. D.; Li, Q. S.; Xiao, H.; Bao, T.; Kantoff, P. W.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Heller, G.; Bryce, A. H.; Armstrong, A. J.; Beltran, H.; Hahn, O. M.; McGary, E. C.; Mehan, P. T.; Goldkorn, A.; Roth, B. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Eggener, S. E.; Chen, R. C.; Heller, G.; Patnaik, A.; Xiao, H.; Weckstein, D.; Mohler, J.; Watson, M.; Taplin, M. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial
    Meeting Abstract

    Feldman, D. R.; Lee, C. H.; Molina, A. M.; Knezevic, A.; Chen, Y.; Chaim, J.; Coskey, D. T.; Ged, Y.; Tickoo, S.; Reuter, V. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: A large single-institution experience
    Journal Article

    Bambury, R. M.; Benjamin, D. J.; Chaim, J. L.; Zabor, E. C.; Sullivan, J.; Garcia-Grossman, I. R.; Regazzi, A. M.; Ostrovnaya, I.; Apollo, A.; Xiao, H.; more...
    The Oncologist (2015)

    Fulltext@MSK | Save